| Aug 7 |
atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference
|
| Jun 26 |
atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference
|
| Jun 20 |
atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a
|
| Jun 5 |
Psychedelic stocks fall as FDA panel rejects MDMA therapy
|
| Jun 4 |
FDA advisory panel fails to endorse psychedelic MDMA therapy for PTSD (updated)
|
| May 31 |
Psychedelic stocks mixed as FDA comments on MDMA therapy
|
| May 31 |
atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference
|
| May 27 |
ATAI: Enormous Potential Upside But No Clarity Yet
|
| May 23 |
atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors
|
